ABSTRACT 70011451°
The present invention provides a stable; ready to use, liquid composition comprising Carfilzomib or its pharmaceutically acceptable salt thereof, a stabilizing agent, a solubilizer, optionally a triglyceride, a tonicity contributing agent, having pH about ...
STABLE LIQUID COMPOSITIONS OF DAPTOMYCIN
ABSTRACT
A stable, aqueous liquid composition comprising, daptomycin or its acceptable salt thereof at a concentration of 26mg/mL or above, and other pharmaceutically acceptable excipients, wherein the composition is free of sugars.
The present invention relates to a stable non-aqueous, ready to dilute liquid pharmaceutical composition comprising (i) melphalan or a pharmaceutically acceptable salt thereof and (ii) polyoxyethylene sorbitan fatty acid esters; wherein the weight ratio of melphalan to polyoxyethylene sorbitan fatty acid esters is f...
The present invention relates to a stable, multidose, ready to use, non-aqueous compositions comprising (i) dantrolene or pharmaceutically acceptable salts thereof; (ii) non-aqueous solvent system suitable for injection; wherein dantrolene was substantially dissolved in the non-aqueous solvent system; wherein non-aq...
The present invention relates to stable long acting inhalation composition comprising indacaterol or its acceptable salts at a concentration from about 15 mcg/mL up to about 150 mcg/mL, and optionally comprising one or more anticholinergic agent. It also relates to use of such compositions for the prevention and/or ...
The present invention relates to a method for inhibiting the growth of the paclitaxel droplet size in a homogenized emulsion, during the preparation of paclitaxel nanoparticle, by diluting the homogenized emulsion with water or aqueous media within 30 minutes of homogenized emulsion formation. The invention also rel...
The present invention relates to a simple, convenient, user-friendly, ready to administer pre-filled syringe injection device, for delivery of medication composition used for the prophylaxis and treatment of vitamin K deficiency bleeding in the neonates and other age groups.
The present invention relates to pharmaceutical composition comprising combination of Lifitegrast and Loteprednol etabonate along with one or more pharmaceutically acceptable excipients for the treatment of dry eye disease.
ABSTRACT
“STABLE PHARMACEUTICAL COMPOSITIONS OF HYDROCORTISONE OR COMBINATIONS THEREOF”
The present invention relates to a stable pharmaceutical composition of corticosteroid and optionally other active agent(s). The present invention relates to a stable pharmaceutical composition of hydrocortisone and optiona...
The present invention relates to a stable GLP-2 peptide injectable composition, comprising GLP-2 peptide agent comprises of sodium; wherein the GLP-2 peptide agent is teduglutide or h[Gly2]GLP-2 and one or more pharmaceutically acceptable excipient(s).